N/A N=27 The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides
Overactive Bladder
Primary: Change in the Relative Abundance of Lactobacillus — 0.143 proportion of total microbes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16 Surface Stimulation for Female Sexual Dysfunction
Female Sexual Dysfunction
Primary: 6 Weeks - Total FSFI Score — 26.0; 17.4 score on a scale — p=0.109
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
N/A N=400 Improving Care for Women With Urinary Incontinence (EMPOWER)
Urinary Incontinence
Primary: Change in Patients' UI Symptoms as Measured by International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) — 8.4; 9.0; 9.9; 8.9…
N/A N=2 Self-Catheterization Mirror System for Female Patients
Spinal Cord Injury
Primary: System Usability Scale — 4; 7 score on a Likert scale
N/A N=56 Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
Urethral Sphincter Activity
Primary: Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG — -18; 10; 11; -15 microvolts — p=>0.05
N/A N=100 Laser Therapy for Treatment of Urogenital Symptoms in Women
Genitourinary System; Disorder, Female · Burning Vagina · Dyspareunia
Primary: Patient Global Impression of Improvement (PGI-I) Score at 4 Weeks After Initial Treatment — 2.66 score on a scale
Phase 4 N=35 Investigation of the Effect of the Female Urinary Microbiome on Incontinence
Overactive Bladder · Incontinence · Nocturia
Primary: Change in the Relative Abundance of Lactobacillus — 0.275 proportion of total microbes
Phase 4 N=20 Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics
Urinary Incontinence · Urgency Urinary
Primary: Inflammatory Markers in Urine Will be Measured Using Immunoenzyme Assays to Measure the Interaction of Anticholinergic Treatment and the Inflammatory Milieu. — 2.192…
N/A N=120 Educating Women About Pelvic Floor Disorders During Pregnancy
Pelvic Floor Disorders · Stress Urinary Incontinence · Pelvic Organ Prolapse
Primary: Prolapse and Incontinence Knowledge Questionnaire (PIKQ) — 17; 17; 21; 21 score on a scale
N/A N=139 Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection in Adult Women
Recurrent Urinary Tract Infection in Adult Women
Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…
N/A N=221 Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence
Urinary Incontinence
Primary: Change of Stamey Grade From Baseline to 12 Months. — -1.17 units on a scale — p=<0.001
N/A N=79 Trial of Tibial Nerve Stimulation for Treating Sexual Dysfunction
Female Sexual Dysfunction
Primary: Female Sexual Function Index (FSFI) — 16.72; 16.88; 22.02; 21.22 score on a scale
Phase 4 N=25 Preventing Recurrent UTI With Vaginal Estrogen
Recurrent Urinary Tract Infection · Urinary Tract Infections · Cystitis Recurrent
Primary: Change in Vaginal Microbiota — 2.75 change in percent relative abundance
N/A N=100 Trial Comparing Outpatient Flexible to Rigid Cystoscopy in Females
Pain
Primary: Post Procedural Complications, Including Frequency, Urgency, Infection and Time to Resolution of These Symptoms Between the Two Procedures. — 17; 15; 5; 15 participants
Phase 3 N=132 Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery
Urinary Retention · Lower Urinary Tract Symptoms · Stress Urinary Incontinence
Primary: Postoperative Urinary Retention — 16; 5 Participants
N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Phase 4 N=154 Nitrofurantoin Prophylaxis During Catheter-managed Acute Urinary Retention After Pelvic Reconstructive Surgery
Pelvic Organ Prolapse
Primary: Number of Participants Experiencing Urinary Tract Infection Within 6 Weeks of Surgery — 13; 13 Participants — p=0.97
N/A N=250 Web-based Management of Female Stress Urinary Incontinence
Female Stress Urinary Incontinence
Primary: International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) — 10.3; 10.4; 7.3; 6.9 units on a scale — p=0.27
Phase 4 N=242 Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection
Urinary Tract Infections
Primary: Urinary Tract Infection — 11; 12 UTI
Phase 3 N=85 An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
Overactive Bladder
Primary: Average Number of Voids Per Day — NA; NA Average Number of Voids
Phase 4 N=163 Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)
Urinary Tract Infection
Primary: Urinary Tract Infections — 18; 10 participants
N/A N=12 Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection
Urinary Tract Infections
Primary: Prevalence of Urinary Tract Infections (UTI) — 28.6; 60; 71.4; 40 percentage of subjects — p=0.034
N/A N=18 Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home
Overactive Bladder
Primary: Change in Urge Incontinence Episodes — 3.9 UUI
Phase 3 N=97 A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)
Urinary Tract Infections
Primary: Percentage of Participants Achieving Clinical Symptom Improvement at 24 Hours (±4 Hours) — 54.4 Percentage of participants
Phase 4 N=132 Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence
Urinary Bladder, Overactive
Primary: Change in OAB Symptoms Post Pubovaginal Sling Operation — 63; 21; 4 participants — p=0.001
Phase 2 N=134 Bacterial Genomic Sequencing in Overactive Bladder
Overactive Bladder
Primary: Bacterial Genomic Sequencing — 25; 11; 3; 6 participants
N/A N=12 Uroflow Measurements in Healthy Volunteers
Healthy
Primary: Voided Volume — 306 mL
N/A N=8 A Feasibility Device Study to Prevent Female Urinary Stress Incontinence
Stress Incontinence, Female
Primary: Pad Weight Difference — 0.0; 0.0; 0.0; 0.3 grams — p=0.0469
Phase 2 N=370 Gentamicin Intravesical Efficacy for Infection of Urinary Tract
Postoperative Urinary Tract Infection · Pelvic Organ Prolapse · Stress Urinary Incontinence
Primary: Post-operative Urinary Tract Infection — 19; 20 Participants